Andy Anderson, a partner with the firm since 1983, concentrates his practice on transactions involving intellectual property - especially biotechnology licenses and collaborations, software and Internet agreements, technology transfer from research institutions, and international licensing and strategic partnerships. He also conducts an active trademark practice, and provides advice relating to research conflicts of interest.
•Represented biotechnology and pharmaceutical companies in major collaborations, including transactions involving foreign entities.
•Negotiated licenses and sponsored research agreements between research institutions and biotechnology companies.
•Advised a large research institution on its intellectual property, technology-transfer policies and on translational activities.
•Provided detailed analysis and comparison of intellectual-property, conflicts, and technology-transfer policies at U.S. universities for a European technology transfer organization.
•Handles the worldwide trademark portfolio of a large international software company.
•Handles technology transfer matters for a Boston research institution.
•Evaluated trademarks and publicity rights issues for a nonprofit foundation making use of the name of a deceased author.
•Oversees trademark, copyright and contract issues for a publisher of educational materials.
•Handles a variety of intellectual property issues in the context of mergers and acquisitions and in the settlement of disputes.
License agreement with major university
In April 2013, our Licensing and Collaborations lawyers helped Agalimmune Limited, a portfolio company of Loxbridge Research LLP based in the United Kingdom, in the exclusive patent and know-how license agreement with a large research university.
Forma Therapeutics Series C Preferred Stock Financing
In 2012, a team of lawyers in Boston represented Forma Therapeutics in the Series C1 Preferred Stock financing in portfolio tracking shares to Lilly Ventures and Novartis Bioventures.
Viamet Pharmaceuticals, Inc. Reorganization and Spin-off
In December 2011, our lawyers represented North Carolina-based Viamet Pharmaceuticals, Inc. in a reorganization under which Viamet Pharmaceuticals, Inc. became a wholly-owned subsidiary of a new parent LLC entity, Viamet Pharmaceuticals Holdings, LLC. and VPS-1, Inc., a spin-off.
Forma Therapeutics, Inc. Reorganization and Spin-off
A team of our lawyers represented Cambridge, MA-based biopharmaceutical company, Forma Therapeutics, Inc. in the December 2011 reorganization and effected spin-off of wholly-owned subsidiary
Facebook Terms and Conditions Held Enforceable Against Minors Digilaw Blog
March 28, 2012
Deadline Approaches for Compliance with Massachusetts Pharmaceutical and Medical Device Manufacturer Conduct Regulations
Intellectual Property Bulletin - Spring 2007
April 17, 2007
Intellectual Property Bulletin - Summer 2006
August 31, 2006
Madrid Protocol Arrives at Last for U.S. Trademark Owners
December 17, 2003
Sublicense Rights - A Key Issue in Technology Licensing
February 7, 2003
SJC Allows Counsel to Speak Directly with Employees of an Adverse Party
March 25, 2002
U.K. Data Protection Act and U.S. Companies
March 21, 2002
Privacy Statements and Web Sites
March 21, 2002
Edwards Wildman's Boston Team Conducts 'Master Class' for Biotech Startups
March 11, 2014
The Firm is Recognized in the American Lawyer
July 7, 2008
Attorneys recognized at EAPD's Second Annual Pro Bono Award Reception
June 25, 2008
Firm Represents Takeda Pharmaceutical Company Limited in $8.8 Billion Acquisition of Millennium Pharmaceuticals
April 10, 2008
How Should Inventors be Compensated for Their Contributions to U.S. Patents?